Literature DB >> 34214960

Comorbid Insomnia and Sleep Apnea: mechanisms and implications of an underrecognized and misinterpreted sleep disorder.

Miguel Meira E Cruz1, Meir H Kryger2, Charles M Morin3, Luciana Palombini4, Cristina Salles5, David Gozal6.   

Abstract

Sleep-disordered breathing (SDB) and insomnia have long been recognized as important sleep disrupters often associated with increased morbidity and mortality. Although they are often seen as divergent conditions, mainly because their cardinal symptoms (excessive daytime sleepiness, and sleep loss) differ, these two sleep disorders present with many common symptoms, which may hinder diagnosis and treatment. In addition to possible bidirectional pathways between SDB and insomnia, other factors such as circadian timing may play a role. In this paper, we review the mechanisms, differential clinical aspects, and implications of Comorbid Insomnia and Sleep Apnea, sometimes termed COMISA.
Copyright © 2021 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  COMISA; Comorbid insomnia and Sleep Apnea; Comorbid insomnia and sleep disordered breathing; Insomnia; Sleep-disordered breathing

Mesh:

Year:  2021        PMID: 34214960     DOI: 10.1016/j.sleep.2021.05.043

Source DB:  PubMed          Journal:  Sleep Med        ISSN: 1389-9457            Impact factor:   3.492


  3 in total

1.  Insomnia, Sleep Apnea, and Circadian Misalignment as a "Three-arm" Contributor to Anxiety and Depression During Pregnancy.

Authors:  Miguel Meira E Cruz; Alexander Sweetman
Journal:  Sleep Vigil       Date:  2021-08-16

2.  Risk of Cardiovascular Disease in Apnoeic Individuals: Role of Comorbid Insomnia Disorder.

Authors:  Matthieu Hein; Benjamin Wacquier; Jean-Pol Lanquart; Gwenolé Loas
Journal:  Life (Basel)       Date:  2022-06-23

3.  Depression, anxiety, and insomnia symptoms among patients with COVID-19: It might be too soon for conclusions.

Authors:  Lucas Gonzaga; Miguel Meira E Cruz; Cristina Salles
Journal:  J Psychosom Res       Date:  2021-07-07       Impact factor: 3.006

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.